Epidermal growth factor receptor and variant III targeted immunotherapy

Kendra L. Congdon, Patrick C. Gedeon, Carter M. Suryadevara, Hillary G. Caruso, Laurence J.N. Cooper, Amy B. Heimberger, John H. Sampson*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated approach undertaken must work together to maximize efficacy with safety. Selected tumor-specific targets can spare potential toxicity to normal tissue; however, they are far less common than tumor-associated antigens and may not be present on all patients. In the context of immunotherapy for high-grade glioma, 2 of the most prominently studied antigens are the tumor-associated epidermal growth factor receptor and its tumor-specific genetic deletion variant III. In this review, we will summarize the immune-mediated strategies employed against these targets as well as the caveats particular to these approaches.

Original languageEnglish (US)
Pages (from-to)viii20-viii25
StatePublished - Sep 12 2014
Externally publishedYes


  • epidermal growth factor receptor
  • glioma
  • immunology
  • immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Epidermal growth factor receptor and variant III targeted immunotherapy'. Together they form a unique fingerprint.

Cite this